Longevity Biotechnology Association

Largest proteomics study to date! Delays in diagnosing many diseases stem from a lack of objective biomarkers. A study involving 41,931 individuals from the UK Biobank integrated plasma protein measurements with clinical information to predict the 10-year incidence of 218 diseases. Protein-based models outperformed traditional clinical models for 67 diseases and those using additional assay data for 52 diseases. Validation in the EPIC-Norfolk study confirmed these findings. These results suggest that plasma protein signatures can provide valuable predictions for both common and rare diseases.

Can a #biological #age test keep you healthy? The Buck shared pros and cons of these tests with the Today Show.

LBA member and Genflow Biosciences CEO Dr. Eric Leire shared updates on their progress and future plans. Key points include: -Secured funding to advance programs, particularly lead candidate GF-1002, with guidance from the FDA and European Agency. -Focus on global reach, aligning efforts in Europe and the US. -Promising results in clinical trials for dogs with sirtuin 6 (SIRT6) variants, which could expedite human trials. -Collaboration with Exothera S.A. for cost-effective large-scale production of SIRT6 variants. -Upcoming focus on clinical trials for MASH and advancing the dog study, with potential veterinary pharmaceutical collaborations.

Great insights from LBA member and BioAge CEO, Kristen Fortney! During the three-day Aspen Ideas Health event, Kristen provided fantastic perspectives on longevity science and how it’s reshaping the future of human health.

The full recording of the "AI For Longevity Drug Discovery: Breakthrough and Challenges" webinar is now available. On June 18, 2024, the American Federation for Aging Research (AFAR) hosted a webinar for scientific and entrepreneurial professionals, offering insights into AI's real-world applications in drug discovery, along with its challenges and breakthroughs. The discussion, coordinated by AFAR Board Member Sergey Young (CEO of the Longevity Vision Fund), was moderated by Longevity Biotechnology Association member Dr. Kristen Fortney of BioAge and featured experts Dr. Hanadie Yousef of Juvena Therapeutics, Dr. Alex Zhavoronkov of Insilico Medicine, and Dr. Ben Blue of Ora Biomedical, Inc. Watch: https://lnkd.in/g4rtbBpQ #DrugDiscovery #BiotechTherapeutics #AgingResearch #AFAR #LongevityVisionFund #BioAge #JuvenaTherapeutics #InsilicoMedicine #OraBiomedical

The LBA is proud to partner with XPRIZE Healthspan, with LBA co-founder Dr. Nir Barzilai serving on the Advisory Board. Traditional medicine treats symptoms as they appear, extending life without proactively improving health, often leading to poor quality of life and economic challenges in later years. This competition aims to foster scientific breakthroughs in creating proactive therapeutics that reduce chronic age-related diseases, increase healthspan, and enhance quality of life. Successful trials could revolutionize our approach to aging, establish guidelines for healthy aging, and reduce healthcare costs. This initiative seeks to democratize health and unlock the full potential of aging.

Exciting news! The American Federation for Aging Research is hosting a free webinar on June 18 titled “AI Drug Discovery for Longevity.” Join biotech leaders as they discuss the breakthroughs and challenges that AI brings to Longevity Drug Discovery. The event will be held online and is expected to attract a diverse audience, including scientists, students, enthusiasts, donors, and AI experts. Confirmed speakers include Alex Zhavoronkov from Insilico Medicine, Hanadie Yousef from Juvena Therapeutics, and Mitchell Lee from Ora Biomedical, with Kristen Fortney from BioAge as the moderator. Mark your calendars for Tuesday, June 18, from 1 PM to 2 PM ET. Learn more and RSVP here: https://ow.ly/TF9q50RYQjr

Great insight from James Peyer, PhD, LBA member and founder of Cambrian Bio, on the economics of developing longevity drugs. Check out his latest newsletter to learn more about why these medications may be more affordable than you think and how they will still be profitable for companies.

The Longevity Biotechnology Association (LBA) is excited to announce its Tier 3 #sponsorship of the 11th Aging Research & Drug Discovery (ARDD) Meeting, taking place August 26-30, 2024, at the University of Copenhagen. ARDD 2024 will feature a lineup of contributions from academic institutions, industry leaders, and the LBA. This year, #ARDD partners with #XPRIZE Healthspan, hosting its first Team Summit at the event to emphasize a shared commitment to extending healthy lifespans. The conference will also include Longevity Medicine Day, attracting healthcare professionals to discuss integrating #geroscience and AI into clinical practice. ARDD aims to bridge clinical, academic, and commercial research to extend healthy lifespans globally. Learn more - https://lnkd.in/gyvuYC-8

A study by the Buck Institute for Aging Research found that the accumulation of senescent cells contributes to aging and related diseases, but eliminating these cells can improve health. Research shows that inhibiting sodium-glucose co-transporter 2 (SGLT2) with canagliflozin enhances the clearance of senescent cells, improving age-related changes. In obese mice, canagliflozin reduced senescent cells in visceral fat, decreased inflammation, and improved metabolism, unlike insulin. It also extended the lifespan of prematurely aging mice. Canagliflozin upregulated a compound that boosted immune clearance of senescent cells by downregulating programmed cell death-ligand 1, suggesting that SGLT2 inhibition indirectly promotes the removal of senescent cells. #SenescentCells #Canagliflozin #SGLT2Inhibitor #LongevityScience #MetabolicHealth #ImmuneBoost #ObesityResearch